Market Overview

UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst

Related VNDA
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews

Jefferies upgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Hold to Buy and raised the price target from $3.50 to $6.00.

Jefferies commented, "We're finally giving credit for tasimelteon given 1) surprisingly good recent Non24 Ph.3 data w/clinical sleep efficacy which likely improves FDA receptivity, 2) orphan pricing not confounded by ‘depression' efforts, and 3) approaching regulatory catalysts. We still think it's far from a slam dunk, but even conservatively discounted Tasi contribution is likely big upside from current negative EV level."

Vanda Pharmaceuticals closed at $3.95 on Wednesday.

Posted-In: JefferiesAnalyst Color Upgrades Analyst Ratings

 

Most Popular

Related Articles (VNDA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free